Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 10:13 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2497–2520 of 26,669 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: CTRL Clear all

Conditions: Dry Eye Disease (DED)
Interventions: DFL24498, Vehicle; Drug · Other
Lead sponsor: Dompé Farmaceutici S.p.A; Industry
Eligibility: 18 Years and older
Enrollment: 417 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 24
States / cities: Chandler, Arizona • Azusa, California • Glendale, California + 21 more

Conditions: Delayed Graft Function
Interventions: Everolimus, Tacrolimus, Mycophenolate mofetil (MMF/MPA); Drug
Lead sponsor: Matthew Cooper; Other
Eligibility: 18 Years to 65 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Pain, Ventilatory Depression
Interventions: hydromorphone; Drug
Lead sponsor: Northwestern University; Other
Eligibility: 21 Years to 30 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Alcohol Use Disorder
Interventions: Arbaclofen Placarbil, Placebo; Drug
Lead sponsor: Indivior Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Oakland Park, Florida

Conditions: Healthy Adult Subjects
Interventions: ONO-2952, Placebo; Drug
Lead sponsor: Ono Pharma USA Inc; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2011
U.S. locations: 1
States / cities: Austin, Texas

Conditions: HIV Infections
Interventions: BG505 SOSIP.664 gp140, adjuvanted, Placebo; Biological
Lead sponsor: International AIDS Vaccine Initiative; Network
Eligibility: 18 Years to 50 Years
Enrollment: 61 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2023
U.S. locations: 2
States / cities: Boston, Massachusetts • Seattle, Washington

Conditions: Attention Deficit Disorder With Hyperactivity
Interventions: Neutral salts of dextroamphetamine sulfate, USP, amphetamine sulfate, USP, d-amphetamine saccharate, d,I-amphetamine aspartate monohydrate; Drug
Lead sponsor: Shire; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 4
States / cities: Little Rock, Arkansas • Irvine, California • Las Vegas, Nevada + 1 more

Conditions: Focal Epilepsy
Interventions: BHV-7000, Placebo; Drug
Lead sponsor: Biohaven Therapeutics Ltd.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 390 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 50
States / cities: Peoria, Arizona • Phoenix, Arizona • Little Rock, Arkansas + 41 more

Conditions: Facial Papulopustular Rosacea
Interventions: FMX103 minocycline foam 1.5%, Vehicle foam; Drug
Lead sponsor: Vyne Therapeutics Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 751 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 54
States / cities: Tucson, Arizona • Fremont, California • Los Angeles, California + 46 more

Conditions: Gastric Cancer, Gastric Metaplasia, Gastric Dysplasia
Interventions: White light biopsy, Protocolled, Narrow Band Imaging Guided Biopsy; Procedure
Lead sponsor: University of Southern California; Other
Eligibility: 18 Years and older
Enrollment: 220 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2023
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Pain
Interventions: Ear Acupuncture, Standard Treatment; Other · Drug
Lead sponsor: Mike O'Callaghan Military Hospital; Federal
Eligibility: 18 Years and older
Enrollment: 49 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Nellis Air Force Base, Nevada

Conditions: Small Fiber Neuropathy
Interventions: Evoke SCS system; Device
Lead sponsor: TriCity Research Center; Industry
Eligibility: 19 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Grand Island, Nebraska

Conditions: Distal Radius Fracture
Interventions: Standardized Preoperative Education, Standard of care, Preoperative and postoperative questionnaires; Behavioral
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Sexual Health
Interventions: Ashwagandha, Placebo; Dietary Supplement · Other
Lead sponsor: SF Research Institute, Inc.; Network
Eligibility: 30 Years to 50 Years · Male only
Enrollment: 45 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Alzheimer's Disease
Interventions: Solanezumab, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 55 Years to 85 Years
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 98
States / cities: Phoenix, Arizona • Sun City, Arizona • Tucson, Arizona + 80 more

Conditions: Subacromial Impingement, Subacromial Impingement Syndrome
Interventions: Ketorolac Tromethamine, Methylprednisolone Acetate; Drug
Lead sponsor: The University of Texas Medical Branch, Galveston; Other
Eligibility: 18 Years to 100 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Galveston, Texas

Conditions: Alzheimer's Disease
Interventions: Albumin 5%, Albumin 20%, Immunoglobulin; Biological
Lead sponsor: Instituto Grifols, S.A.; Industry
Eligibility: 55 Years to 85 Years
Enrollment: 347 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2018
U.S. locations: 22
States / cities: Sacramento, California • Denver, Colorado • Washington D.C., District of Columbia + 17 more

Conditions: Urea Cycle Disorders
Interventions: HHLivC; Biological
Lead sponsor: Cytonet GmbH & Co. KG; Industry
Eligibility: 1 Day to 5 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 4
States / cities: Palo Alto, California • San Diego, California • New Haven, Connecticut + 1 more

Conditions: Type 1 Diabetes, De Novo Lipogenesis
Interventions: Oral Glucose Tolerance Test; Diagnostic Test
Lead sponsor: Yale University; Other
Eligibility: 13 Years to 22 Years
Enrollment: 7 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: HOCM, Hypertrophic Obstructive Cardiomyopathy
Interventions: Mavacamten, Placebo; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 112 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 21
States / cities: Los Angeles, California • Stanford, California • New Haven, Connecticut + 16 more

Conditions: Amyloidosis, Amyloid Cardiomyopathy, Transthyretin Amyloidosis, Cardiomyopathies, Heart Diseases, Polyneuropathies
Interventions: Acoramidis, Placebo oral tablet; Drug
Lead sponsor: Eidos Therapeutics, a BridgeBio company; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 587 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2032
U.S. locations: 40
States / cities: La Jolla, California • Los Angeles, California • San Francisco, California + 31 more

Conditions: Attention Deficit Hyperactivity Disorder
Interventions: Hypericum perforatum, Placebo; Drug · Other
Lead sponsor: National Center for Complementary and Integrative Health (NCCIH); NIH
Eligibility: 6 Years to 17 Years
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 1
States / cities: Kenmore, Washington

Conditions: Bipolar Depression
Interventions: Palmitoylethanolamide (PEA), Placebo, Treatment as Usual (TAU); Drug
Lead sponsor: Rodrigo Machado-Vieira, MD, PhD, MSc; Other
Eligibility: 18 Years to 70 Years
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Ulcerative Colitis
Interventions: Low Dose Budesonide, High Dose Budesonide, Placebo; Drug
Lead sponsor: Bausch Health Americas, Inc.; Industry
Eligibility: 5 Years to 17 Years
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 4
States / cities: Garden Grove, California • Indianapolis, Indiana • The Bronx, New York + 1 more

Search by objective public record fields.

An Exploratory Efficacy and Safety Study of DFL24498 Topical Ophthalmic Solution Compared With Vehicle in Participants With Dry Eye Disease

A Pilot Study Comparing the Safety and Efficacy of Everolimus With Other Medicines in Recipients of ECD/DCD Kidneys

Hydromorphone Pharmacokinetic-Pharmacodynamic Fingerprint

A Dose-Escalation Study to Determine the Maximum Tolerated Dose of Arbaclofen Placarbil in Subjects With Alcohol Use Disorder

Single-Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ONO-2952 in Healthy Adult Subjects

A Randomized, Double-blinded, Placebo-controlled, Dose-escalation Phase 1 Clinical Trial to Evaluate the Safety and Immunogenicity of Recombinant HIV Envelope Protein BG505 SOSIP.664 gp140 Vaccine, Adjuvanted, in Healthy, HIV-1 Uninfected Adults

Safety and Efficacy of SPD465 in Adults With ADHD

Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy

A Study (Study 1) to Evaluate the Safety and Efficacy of FMX103 1.5% Topical Minocycline Foam in the Treatment of Facial Papulopustular Rosacea

Narrow Band Imaging for Gastric Neoplasia

Ear Acupuncture for Pain Associated With Ambulatory Arthroscopic Knee Surgery

Pilot Study to Evaluate Changes in Intra-Epidermal Nerve Fiber Density (IENFD) in Patients With Small-Fiber Neuropathy

Preoperative Education in Hand and Wrist Surgery

Role of Ashwagandha Extract (Capsule KSM-66 300 mg) in Improving Sexual Health in Healthy Men

A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease

Subacromial Methylprednisolone Versus Ketorolac for Shoulder Impingement

A Study to Evaluate Albumin and Immunoglobulin in Alzheimer's Disease

Human Heterologous Liver Cells for Infusion in Children With Urea Cycle Disorders

Pathogenesis of the Cardiometabolic Risk in Youth With Type 1 Diabetes

A Study to Evaluate Mavacamten in Adults With Symptomatic Obstructive HCM Who Are Eligible for Septal Reduction Therapy

Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant

Herbal Treatment for Attention Deficit Hyperactivity Disorder (ADHD)

A Trial of the Fatty Acid Amide Hydrolase Inhibitor Palmitoylethanolamide in Bipolar Depression

Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Budesonide Extended-release Tablets in Pediatric Subjects Aged 5 to 17 Years With Active, Mild to Moderate Ulcerative Colitis